Omnitarg (2C4) is a monoclonal antibody and the first in a new class of agents developed by Genentech known as HER dimerization inhibitors (HDIs). It was developed to bind to the HER-2 receptor and block the interaction between HER-2 and other HER family members (i.e. HER1/EGFR HER2 HER3 and HER4). Technically it is designed to target tumors that have normal " rather than ""overexpressed" " HER2 protein. It is relevant because it may one day represent the Herceptin equivalent"" treatment for patients who are not HER-2 positive or who are not ""strongly"" HER-2 positive.
Importantly" the positive study data relates not only to breast cancer but to other cancers as well (e.g. prostate lung ovarian colon pancreas and sarcoma). |
All times are GMT -7. The time now is 07:13 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021